ORAPI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.8 EUR | -5.23% |
|
-4.29% | -9.94% |
| Apr. 17 | Orapi SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 12 | Orapi: Groupe Paredes holds almost 90% of the capital | CF |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.4 times its sales.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Most analysts recommend that the stock should be sold or reduced.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Commodity Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -9.94% | 43.23M | - | ||
| +3.74% | 102B | A- | ||
| -6.95% | 60.79B | A- | ||
| +75.24% | 48.86B | B | ||
| +13.54% | 37.96B | B | ||
| +0.44% | 32.37B | A- | ||
| +11.92% | 20.64B | B- | ||
| +10.77% | 16.58B | C+ | ||
| +8.20% | 13.93B | B- | ||
| -4.15% | 13.25B | B |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ORAP Stock
- Ratings ORAPI
